Susquehanna International Group
RANI icon

Susquehanna International Group’s Rani Therapeutics RANI Stock Holding History

Susquehanna International Group’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$138K Buy
188,222
+131,400
+231% +$168K ﹤0.01% 12094
2025
Q4 		$76.7K Buy
+56,822
New +$85.7K ﹤0.01% 11584
2025
Q2 		– Sell
-16,554
Closed -$13.5K – 13540
2025
Q1 		$20.9K Buy
+16,554
New +$24.5K ﹤0.01% 12100
2023
Q2 		– Sell
-70,772
Closed -$365K – 12940
2023
Q1 		$365K Buy
+70,772
New +$426K ﹤0.01% 9270

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Susquehanna International Group's RANI Position: Q1 2026 in Review

Susquehanna International Group increased its Rani Therapeutics (RANI) stake by 231% in Q1 2026, buying an estimated $168K and bringing the position to 188,222 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #12094.

Susquehanna International Group first reported a position in RANI in Q1 2023 and has held it in 4 quarters since. The position peaked at $365K in Q1 2023. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Susquehanna International Group held 188,222 shares of Rani Therapeutics worth $138K as of Q1 2026.
  • Susquehanna International Group bought 131,400 Rani Therapeutics shares in Q1 2026, an estimated $168K.
  • Rani Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12094 holding.
  • Susquehanna International Group first reported a position in Rani Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • Susquehanna International Group's Rani Therapeutics position peaked at $365K in Q1 2023.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.